These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37947105)

  • 1. Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.
    Huck DM; Weber B; Parks S; Divakaran S; Brown JM; Bibbo CF; Barrett L; Hainer J; Bay C; Martell L; Kogelman L; Triant VA; Chu J; Lin NH; Melbourne K; Sax PE; Di Carli MF
    J Am Heart Assoc; 2023 Nov; 12(22):e029541. PubMed ID: 37947105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis.
    Brenner IR; Flanagan CF; Penazzato M; Webb KA; Horsfall SB; Hyle EP; Abrams E; Bacha J; Neilan AM; Collins IJ; Desmonde S; Crichton S; Davies MA; Freedberg KA; Ciaranello AL
    Lancet Glob Health; 2024 Dec; 12(12):e2068-e2079. PubMed ID: 39577977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.
    Funderburg NT; Huang SSY; Cohen C; Ailstock K; Cummings M; Lee JC; Ng B; White K; Wallin JJ; Downie B; McComsey GA
    Front Immunol; 2024; 15():1488799. PubMed ID: 39600696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    Expert Rev Anti Infect Ther; 2024 Oct; 22(10):877-884. PubMed ID: 37927079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.
    Tiendrebeogo T; Malateste K; Poda A; Minga A; Lahiri CD; Ezechi O; Ekouevi DK; Ofotokun I; Jaquet A;
    J Int AIDS Soc; 2024 Dec; 27(12):e26371. PubMed ID: 39604062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial.
    Ballif M; Braun D; Calmy A; Bernasconi E; Cavassini M; Tissot F; Stoeckle M; Schmid P; Fux CA; Van der Valk M; Brinkman K; Mudrikova T; Bonnet F; Leleux O; Saúde M; Hirter D; Schwab N; Limacher A; Rintelen F; Kouyos R; Haerry D; Zambrano SC; Egloff M; Akre C; Peytremann-Bridevaux I; Rauch A; Wandeler G; Surial B
    BMJ Open; 2024 Nov; 14(11):e094912. PubMed ID: 39578038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The progress of mother-to-child transmission of Human Immunodeficiency Virus (HIV) after Dolutegravir (DTG) optimization program: evidence from a multicenter cohort study in Ethiopia.
    Gedefaw A; Tadesse BT; Tadesse S; Kebede B; Hussen S; Hailu D; Berhan Y; Makonnen E; Vella S; Aklillu E
    BMC Public Health; 2024 Dec; 24(1):3367. PubMed ID: 39627710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial.
    Rossetti B; Ferrara M; Taramasso L; Bai F; Lombardi F; Ciccarelli N; Durante M; Alladio F; Bonazza F; Rancan I; Montagnani F; Di Biagio A; Monforte AD; Zazzi M; Fabbiani M;
    Infect Dis Ther; 2024 Nov; ():. PubMed ID: 39612159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) Is Elevated and Inversely Related to Coronary Endothelial Function in People With HIV.
    Kikuchi DS; Kwapong YA; Schär M; Weiss RG; Sun K; Brown TT; Piggott DA; Minhas AS; Gerstenblith G; Soleimani-Fard A; Leucker TM; Hays AG
    J Am Heart Assoc; 2024 Dec; 13(23):e035975. PubMed ID: 39575706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
    Bekker LG; Das M; Abdool Karim Q; Ahmed K; Batting J; Brumskine W; Gill K; Harkoo I; Jaggernath M; Kigozi G; Kiwanuka N; Kotze P; Lebina L; Louw CE; Malahleha M; Manentsa M; Mansoor LE; Moodley D; Naicker V; Naidoo L; Naidoo M; Nair G; Ndlovu N; Palanee-Phillips T; Panchia R; Pillay S; Potloane D; Selepe P; Singh N; Singh Y; Spooner E; Ward AM; Zwane Z; Ebrahimi R; Zhao Y; Kintu A; Deaton C; Carter CC; Baeten JM; Matovu Kiweewa F;
    N Engl J Med; 2024 Oct; 391(13):1179-1192. PubMed ID: 39046157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the prevalence of anaemia and its predictors among adults on highly active antiretroviral therapy in the dolutegravir era: a retrospective cross-sectional study.
    Sisay Zewdu W; Molla Zeleke M; Ferede YA; Kassie AB; Singh P; Alemu MA; Desta GT
    BMJ Open; 2024 Sep; 14(9):e086480. PubMed ID: 39242159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus/acquired immune deficiency syndrome antiretroviral therapy initiated on the same day in treatment-naïve people with human immunodeficiency virus: A comparative study of efficacy and regimen.
    Yuan J; Deng C; Li Q; Sun Y; Huang W; Zhang W; Liu M
    Chin Med J (Engl); 2024 Nov; 137(22):2720-2725. PubMed ID: 39501837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryotherapy following total knee replacement.
    Aggarwal A; Adie S; Harris IA; Naylor J
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD007911. PubMed ID: 37706609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.